Dynactin 1 Antibody (B-4): sc-365054

Dynactin 1 Antibody (B-4) is a mouse monoclonal IgG1 antibody that detects Dynactin 1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Dynactin 1 is a crucial component of the dynactin complex, which plays a vital role in cellular transport processes by acting as a bridge between the Dynein motor and its cargo, facilitating the movement of organelles along microtubules. This interaction is essential for various cellular functions, including the proper distribution of organelles during cell division and the maintenance of neuronal integrity. The protein′s structure, characterized by its multisubunit composition, allows for versatile interactions with other proteins, enhancing the functional diversity of Dynein-driven transport mechanisms. Notably, Dynactin 1 is enriched in neurons, where Dynactin 1 supports critical processes such as the formation of the mitotic spindle and cytokinesis, underscoring its importance in both neuronal function and overall cellular health. Anti-Dynactin 1 antibody (B-4) is an invaluable tool for researchers studying these dynamic processes and the underlying mechanisms of cellular transport.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Dynactin 1 Antibody (B-4) References:

1. The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis.  |  Münch, C., et al. 2007. Acta Neurol Scand. 116: 231-4. PMID: 17824900
2. Characterization of DCTN1 genetic variability in neurodegeneration.  |  Vilariño-Güell, C., et al. 2009. Neurology. 72: 2024-8. PMID: 19506225
3. Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.  |  Newsway, V., et al. 2010. Mov Disord. 25: 767-70. PMID: 20437543
4. Autonomic failures in Perry syndrome with DCTN1 mutation.  |  Ohshima, S., et al. 2010. Parkinsonism Relat Disord. 16: 612-4. PMID: 20702129
5. DCTN1 mutations and progressive supranuclear palsy-like phenotype.  |  Fujioka, S., et al. 2014. JAMA Neurol. 71: 655. PMID: 24818686
6. DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy.  |  Honda, H., et al. 2018. Parkinsonism Relat Disord. 51: 105-110. PMID: 29499916
7. A Novel Cosegregating DCTN1 Splice Site Variant in a Family with Bipolar Disorder May Hold the Key to Understanding the Etiology.  |  Hallen, A. and Cooper, AJL. 2020. Genes (Basel). 11: PMID: 32325768
8. Larotrectinib followed by selitrectinib in a novel DCTN1-NTRK1 fusion undifferentiated pleomorphic sarcoma.  |  Goh, XN., et al. 2021. J Oncol Pharm Pract. 27: 485-489. PMID: 32693686
9. Spindle cell/sclerosing rhabdomyosarcoma with DCTN1::ALK fusion: broadening the molecular spectrum with potential therapeutic implications.  |  Fung, CK., et al. 2022. Virchows Arch. 480: 927-932. PMID: 35229187
10. Perry syndrome: Novel DCTN1 mutation in a large kindred and first observation of prodromal disease.  |  Dulski, J., et al. 2023. Parkinsonism Relat Disord. 112: 105481. PMID: 37336025

The preferred Dynactin 1 antibody is Dynactin 1 Antibody (A-2): sc-365274.